About Us

Dr. Hung served as president, chief executive officer and director of Medivation Neurology since its inception in September 2003. He became president and chief executive officer of Medivation, Inc. and a member of the Board of Directors when the Company acquired its subsidiary Medivation Neurology, Inc. in December 2004. From 1998 to 2001, Dr. Hung served as chief scientific officer (1998-1999) and as president, chief executive officer and director (1999-2001) of ProDuct Health, Inc., a privately-held medical device company focused on breast cancer cytological diagnostics. ProDuct Health, Inc was acquired in 2001 by Cytyc Corporation for $167 million after having spent only approximately $22 million in total development costs. From 1996 to 1998, Dr. Hung served in various senior positions at Chiron Corporation, most recently as vice president of lead discovery and development and vice president of new projects. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in biology from Harvard College.

Mr. Machado was appointed chief business officer in December 2009, and has served as chief financial officer since 2004. From 1998 to 2001, he served as vice president, chief financial officer and general counsel (1998-2000) and as senior vice president and chief financial officer (2000-2001) of ProDuct Health, Inc., a privately-held medical device company. From 2001 to 2002, he served as a consultant to Cytyc Corporation to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. From 1996 to 1998, Mr. Machado served as head of business development for new projects (working with Dr. Hung) and in senior business development and legal functions at Chiron Corporation. He received a J.D. cum laude from Harvard Law School and a B.A. and B.S. summa cum laude in German and economics, respectively, from Santa Clara University.

Ms. Cohen was appointed chief commercial officer in September 2011. From 2008 to 2011, Ms. Cohen was president of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization. She also served previously as the vice president, strategic commercial group, of Health Care Systems, Inc., a Johnson & Johnson company accountable for managed markets, contracting, and supply chain, where she was directly responsible for access of Johnson & Johnson products within one of the largest health plans in the country (2007 to 2008). From 1998 to 2007, she worked at Centocor, Inc., a Johnson & Johnson company, in a variety of senior sales roles including, vice president, rheumatology franchise, with direct responsibility for the $1+ billion per year Remicade® U.S. rheumatoid arthritis business and its 170-person sales and marketing team. Ms. Cohen began her career at Solvay Pharmaceuticals in a variety of sales positions (1992-1998). She earned her B.A. from Saint Joseph College.

Ms. Rhodes joined Medivation in June 2012 as our General Counsel, and was appointed Chief Compliance Officer in July 2012 and Corporate Secretary in April 2013. Between May 2006 and June 2012, Ms. Rhodes was an Assistant General Counsel at Pfizer Inc. where she supported the U.S. Primary Care Business and its Primary Care Medicines Development Group, and served as a legal product lead for Pfizer Inc.’s primary care medicines. Prior to joining Pfizer Inc., Ms. Rhodes was an associate in the regulatory law and international trade practice areas at Weil, Gotshal & Manges, LLP from October 2000 to April 2006. Between September 1998 and August 2000, Ms. Rhodes served as a law clerk for Chief Judge Gregory A. Carman on the United States Court of International Trade. Ms. Rhodes received a J.D. from Wake Forest University School of Law and a B.A. in Economics from Newcomb College of Tulane University.

Dr. Seely joined Medivation as chief medical officer in May 2005. From 2002 to 2005, she served as vice president of clinical development at Corgentech, Inc. (Anesiva, Inc.), a biomedical company. She served as vice president of clinical development at ProDuct Health, Inc., a privately-held medical device company, from 2000 to 2001, and subsequently served as vice president of clinical development for Cytyc Health Corporation, a medical device company and subsidiary of Cytyc Corporation, from 2001 to 2002. While there she assisted with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. From 1996 through 2000, she served as an associate director of clinical development at Chiron Corporation. Dr. Seely has led teams running clinical trials in all phases of development in a variety of therapeutic indications. Dr. Seely received an M.D. Alpha Omega Alpha from the University of Oklahoma, College of Medicine and completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital. She is board-certified in internal medicine and endocrinology and metabolism and was on the faculty at the University of California, San Diego prior to joining industry.

Dr. Kelsey joined Medivation in May 2013 as Senior Vice President of New Projects. Dr. Kelsey was previously at Geron Corporation as Executive Vice President, Head of Research & Development and Chief Medical Officer. He joined Geron in April 2009 as Executive Vice President and Chief Medical Officer, Oncology. From June 2002 until April 2009, Dr. Kelsey held various positions at Genentech, Inc., most recently as Vice President, clinical hematology/oncology. From June 2000 to June 2002, Dr. Kelsey was the Director of clinical affairs at Pharmacia Corporation (SUGEN, Inc.) and Director of global clinical development (oncology) at Pharmacia Corporation in Milan, Italy. From July 1993 to June 2000, Dr. Kelsey served as a Senior Lecturer in hematology/oncology at St. Bartholomews and the Royal London School of Medicine and Dentistry and visiting fellow at Vancouver General Hospital and Terry Fox Laboratories. Dr. Kelsey earned his B.Sc. in Pharmacology, M.B., Ch.B., and Doctorate of Medicine (M.D.) degrees from the University of Birmingham in the United Kingdom.